专家评估与不同超声模型诊断卵巢癌的经济学评价
本研究从社会视角对附件肿块诊断策略进行成本效果和预算影响分析,比较RMI、专家主观评估(SA)及新型超声模型。SA诊断准确性最高(90.7%),SR+SA成本最低且具成本节约优势,RMI成本效果概率低。
要点
- SA诊断准确性最高,达90.7%,且成本低于RMI。
- SR+SA成本最低,相比RMI每例节约709欧元。
- 支付意愿低于每增加1%正确诊断350欧元时,SR+SA最具成本效果。
核心结论
- 从成本效果角度,SR+SA可能优于SA,尽管SA诊断准确性最高。
- RMI成本效果概率低,劣于SA、SR+SA和LR2。
研究设计与样本
- 从社会视角进行成本效果和预算影响分析,构建决策树,纳入附件肿块女性的短期成本和效果。
- 效果指标为正确诊断百分比,增量成本效果比表示为每增加1%正确诊断患者的成本。
主要发现
- SA有效性最高,为90.7%(95%CI 77.3-100),相比RMI每例节约398欧元(95%CI -1403至549)。
- SR+SA成本最低,为7180欧元(95%CI 6072-8436),相比RMI每例节约709欧元(95%CI -1628至236),有效性为89.6%(95%CI 75.8-100)。
- 当支付意愿低于每增加1%正确诊断350欧元时,SR+SA最可能具有成本效果。
关键数值与推荐
- SA有效性90.7%(95%CI 77.3-100),成本节约5.0%(每例-398欧元,95%CI -1403至549)相比RMI。
- SR+SA成本7180欧元(95%CI 6072-8436),成本节约9.0%(每例-709欧元,95%CI -1628至236)相比RMI,有效性89.6%(95%CI 75.8-100)。
- RMI成本效果概率<3%。
临床怎么用
- 对于附件肿块诊断,可考虑SR+SA作为具有成本效果优势的策略。
- SA诊断准确性最高,但SR+SA从成本效果角度可能更优。
局限性
- 敏感性分析结果稳健,但研究基于短期成本和效果模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Risk of Malignancy Index (RMI) is commonly used to diagnose adnexal masses. The aim of the present study was to determine the cost-effectiveness of the RMI compared with subjective assessment (SA) by an expert and the following novel ultrasound models: Cost-effectiveness and budget impact analyses were performed from a societal perspective. A decision tree was constructed, and short-term costs and effects were examined in women with adnexal masses. Sensitivity, specificity and the costs of diagnostic strategies were incorporated. Incremental cost-effectiveness ratios were expressed as costs/additional percentage of correctly diagnosed patients. Probabilistic and deterministic sensitivity analyses were performed. Effectiveness was highest for SA (90.7% [95% confidence interval = 77.3-100]), with a cost saving of 5.0% (-€398 per patient [-€1403 to 549]) compared with the RMI. The costs of SR + SA were the lowest (€7180 [6072-8436]), resulting in a cost saving of 9.0% (-€709 per patient [-€1628 to 236]) compared with the RMI, with an effectiveness of 89.6% (75.8-100). SR + SA showed the highest probability of being the most cost-effective when willingness-to-pay was <€350 per additional percentage of correctly diagnosed patients. The RMI had low cost-effectiveness probabilities (<3%) and was inferior to SA, SR + SA and LR2. Budget impact in the Netherlands compared with that of the RMI varied between a cost saving of €4.67 million for SR + SA and additional costs of €3.83 million when implementing ADNEX (cut-off: 10%). The results were robust when tested in sensitivity analyses. Although SA is the best strategy in terms of diagnostic accuracy, SR + SA might be preferred from a cost-effectiveness perspective.
引用
- Meys EMJ, Jeelof LS, Ramaekers BLT, et al. Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer. Eur J Cancer. 2018. PMID: 29957561. doi:10.1016/j.ejca.2018.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。